论文部分内容阅读
目的探讨Α-受体阻滞剂加生物反馈疗法联合治疗Ⅲ B型慢性前列腺炎,慢性盆底疼痛综合征(CP／ CPPS)的疗效。方法对42例符合NIH诊断标准的患者,采用Α-受体阻滞剂加生物反馈疗法联合治疗,总疗程为60D,分别在治疗结束后7D和30D进行复诊和电话随访,评价治疗前后慢性前列腺炎疼痛症状评分(PS)、排尿症状评分(USS)、生活质量评分(QLS)、尿流率(FC)变化等指标。结果治疗前患者疼痛症状评分(PS) 为17．0±1．7。USS为7．0±1．5。QLS为8．0±1．4。治疗结束时PS为7．0+2．1。USS为3．0±1．3。QLS为4．0±1．5。治疗前后相比均有显著差异(P<0．05)。随访1月时PS为9．0±1．7。USS为4．0±1．2。QLS 5．0±1.3。治疗前最大尿流率(MFR)为18．5±3．8,平均尿流率(AFR)为10．4±2．3。治疗后MFR为22．2±4．0,AFR为12．8±2．5。结论Α-受体阻滞剂加生物反馈疗法对ⅢB型慢性前列腺炎具有缓解疼痛症状、改善排尿、提高生活质量的作用,对尿流率下降的患者,可明显增加尿流率指标。
Objective To investigate the effect of combination of A-receptor blocker and biofeedback therapy on type Ⅲ chronic prostatitis and chronic pelvic pain syndrome (CP / CPPS). Methods Forty-two patients with NIH diagnostic criteria were treated with A-receptor blocker combined with biofeedback therapy for a total duration of 60 days. The patients were followed up for 7 days and 30 days after the end of treatment, respectively. The rates of chronic prostatitis Inflammatory pain symptom score (PS), voiding symptom score (USS), quality of life score (QLS), urinary flow rate (FC) and other indicators. Results The pain symptom scores (PS) before treatment were 17.0 ± 1.7. USS is 7.0 ± 1.5. QLS is 8.0 ± 1.4. PS was 7.0 + 2.1 at the end of treatment. USS was 3.0 ± 1.3. QLS is 4.0 ± 1.5. Before and after treatment were significantly different (P <0.05). At 1 month follow-up, PS was 9.0 ± 1.7. USS is 4.0 ± 1.2. QLS 5.0 ± 1.3. The pre-treatment maximum flow rate (MFR) was 18.5 ± 3.8 and the mean flow rate (AFR) was 10.4 ± 2.3. MFR after treatment was 22.2 ± 4.0 and AFR was 12.8 ± 2.5. Conclusion A-blocker plus biofeedback therapy can relieve pain symptoms, improve urination and improve quality of life in type Ⅲ B chronic prostatitis. Urinary flow rate can be significantly increased in patients with decreased uroflow rate.